Global Health Ltd
Global Health Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Strong volume growth expected across hospitals, with inpatient volumes increasing by 13% YoY in Q3 FY25. Medanta expects continued volume-driven growth, with inpatient volumes up 13% YoY and outpatient volumes increasing 9% YoY in Q3 FY25.
From Global Health Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Strong volume growth expected across hospitals, with inpatient volumes increasing by 13% YoY in Q3 FY25.
- Expansion of bed capacity ongoing: ~1,000 bed additions planned over next 2 years across Lucknow, Patna, Ranchi, and new facilities like Noida.
- Development of three major greenfield projects (Mumbai Oshiwara, Pitampura, South Delhi) adding ~1,600 beds over 3-4 years.
- Continuous recruitment of clinical talent and investment in infrastructure to support growth.
- Focus on increasing bed occupancy and absolute volumes rather than solely occupancy percentage.
- Increased empanelment with government and corporate healthcare schemes to expand patient base.
2 more points from Global Health Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Global Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total CAPEX guidance for the next 3 to 4 years is around Rs. 3,000 crores (slide 25 of investor presentation).
- Approximately 1,000 bed additions planned over the next two years in existing hospitals (Lucknow, Patna, Ranchi) and Noida.
- Three major Greenfield projects underway with about 1,600 beds: Mumbai Oshiwara (500+ beds), Pitampura (700+ beds), South Delhi Greater Kailash (about 400 beds); these are in various approval/construction stages and expected to take 3-4 years.
- Lucknow hospital expansion includes adding 200 beds within 6 to 9 months, with flexibility for new specialties.
- Ranchi expansion includes operationalizing a ready-made hospital to scale from 200 to 300-350 beds.
2 more points from Global Health Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Global Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Total CAPEX guidance for the next 3 to 4 years is around Rs. 3,000 crores (Page 20).
- This includes projects related to the build-out and expansion of existing hospitals and new specialties (Page 20).
- Approximately 1,000 bed additions are planned over the next two years in existing hospitals like Lucknow, Patna, and Ranchi, including Noida (Page 6).
- Three major greenfield projects are underway totaling about 1,600 beds: Mumbai Oshiwara (500+ beds), Pitampura (700+ beds), and South Delhi Greater Kailash (400 beds); these will take 3 to 4 years to commence operations (Page 6).
2 more points from Global Health Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Global Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.2K Cr, net profit ₹142 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Global Health Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Global Health Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Global Health Ltd Q3 FY25 results?
Strong volume growth expected across hospitals, with inpatient volumes increasing by 13% YoY in Q3 FY25. Medanta expects continued volume-driven growth, with inpatient volumes up 13% YoY and outpatient volumes increasing 9% YoY in Q3 FY25.
What is Global Health Ltd share price analysis?
Global Health Ltd currently shows a neutral. The stock trades at a P/E of 66.2 with a market cap of ₹37,919 Cr. Investors should review the full earnings analysis for detailed insights.
Is Global Health Ltd planning capital expenditure?
Total CAPEX guidance for the next 3 to 4 years is around Rs.
Keep Global Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.